The Covert Legal Strategy to Keep Your Drug Prices High
More Perfect Union・8 minutes read
The Inflation Reduction Act allows Medicare to negotiate drug prices for the first time, benefiting 10 million seniors and saving taxpayers over $100 billion, while the pharmaceutical industry is aggressively suing to stop this new negotiating power despite weak legal arguments. The outcome of these legal battles is uncertain, with the industry aiming to reach the Supreme Court and potentially overturn Medicare's negotiation ability, highlighting the need for collective action to support fair pricing and negotiation.
Insights
- The Inflation Reduction Act empowers Medicare to negotiate drug prices, benefiting millions of seniors and saving taxpayers billions, but faces aggressive opposition from the pharmaceutical industry through multiple lawsuits with weak legal grounds.
- Despite the pharmaceutical industry's strategic legal challenges, Medicare's negotiation power, inspired by successful VA practices, is at risk, highlighting the importance of collective action to protect this significant Democratic victory and ensure fair pricing for all.
Get key ideas from YouTube videos. It’s free
Recent questions
How does the Inflation Reduction Act benefit seniors?
The Inflation Reduction Act allows Medicare to negotiate drug prices for the first time, benefiting 10 million seniors with heart disease, blood cancer, and diabetes. This negotiation power is estimated to save taxpayers $102 billion over a decade.
Why is the pharmaceutical industry suing to block Medicare's negotiation power?
The pharmaceutical industry is aggressively suing to block Medicare's new negotiating power because they have been able to prevent Medicare from negotiating drug prices since 2003. This ability has led to lucrative deals for industry insiders who later joined pharmaceutical companies.
How does Medicare's negotiation ability compare to the VA's practices?
Medicare's new negotiation ability, starting with ten drugs and expanding to 60, mirrors successful practices at the VA, where prices were negotiated 54% lower on average than Medicare Part D. This shows the potential for significant cost savings through negotiation.
What legal arguments are the pharmaceutical industry using in their lawsuits against Medicare?
The pharmaceutical industry is fighting back against Medicare's negotiation power through lawsuits claiming theft, free speech violations, and unfair taxation. However, legal experts doubt the industry's chances of success due to the weak legal arguments presented.
Why is the outcome of the legal battles uncertain?
The outcome of the legal battles between the pharmaceutical industry and Medicare is uncertain because the industry is strategically filing lawsuits across different districts to create a circuit split, aiming to reach the Supreme Court. This poses a threat to the rare victory Democrats achieved in giving Medicare negotiation power, emphasizing the need for collective action to support fair pricing and negotiation.
Related videos
The Young Turks
Big Pharma: We're Going To Sue Medicare Over Price Regulations
The Wall Street Journal
How Drug Prices Work | WSJ
DW Documentary
Big Pharma - How much power do drug companies have? | DW Documentary
The Young Turks
Big Pharma Monopolized Drug & Hiked Prices 22 TIMES
CNBC
Why Pharmaceuticals Are So Complicated In The U.S. | CNBC Marathon
Summary
00:00
Medicare vs Pharmaceutical Industry: Legal Battle Ahead
- The Inflation Reduction Act allows Medicare to negotiate drug prices for the first time, benefiting 10 million seniors with heart disease, blood cancer, and diabetes, and saving taxpayers $102 billion over a decade.
- The pharmaceutical industry is aggressively suing to block Medicare's new negotiating power, with nearly ten lawsuits aiming to reach the Supreme Court, despite weak legal arguments.
- In 2003, the pharmaceutical industry influenced Congress to prevent Medicare from negotiating drug prices, leading to lucrative deals for the industry insiders who later joined pharmaceutical companies.
- Medicare's new negotiation ability, starting with ten drugs and expanding to 60, mirrors successful practices at the VA, where prices were negotiated 54% lower on average than Medicare Part D.
- The pharmaceutical industry is fighting back against Medicare's negotiation power through lawsuits claiming theft, free speech violations, and unfair taxation, despite legal experts doubting their chances of success.
- The industry is strategically filing lawsuits across different districts to create a circuit split, aiming to reach the Supreme Court and potentially overturn Medicare's negotiation ability.
- The outcome of these legal battles is uncertain, with the industry's coordinated legal attack posing a threat to the rare victory Democrats achieved in giving Medicare negotiation power, emphasizing the need for collective action to support fair pricing and negotiation.
